Resveratrol ameliorates irinotecan chemoresistance of colorectal cancer cells by down-regulating EGFR/AKT/mTOR signaling pathway

Li Wang; Hui Shen; Qian-rui Kou; Yu-jue Wang; Jing Zhang; Fang LI; Jing Pang

Return

Resveratrol ameliorates irinotecan chemoresistance of colorectal cancer cells by down-regulating EGFR/AKT/mTOR signaling pathway

Author: Li WANG ¹ ; Hui SHEN ¹ ; Qian-Rui KOU ¹ ; Yu-Jue WANG ¹ ; Jing ZHANG ¹ ; Fang LI ¹ ; Jing PANG ²
Author Information

1. School of Basic Medicine, Medical School of yan'An University
2. Dept of Endocrinology and Metabolism, Affiliated Hospital of yan'An University
Publication Type:Journal Article
Keywords: chemoresistance; colorectal cancer; irinotecan; migration; proliferation; resveratrol
From: Chinese Pharmacological Bulletin 2023;39(12):2280-2287
CountryChina
Language:Chinese
Abstract: Aim To explore the possibility of resveratrol ( RES) combined with irinotecan ( IRI) in the treatment of colorectal cancer ( CRC ) and the underlying molecular mechanism of RES ameliorating IRI chemoresistance of CRC cells. Methods CRC cells used in this study were HT-29 and RKO cells. The effects of RES, IRI and their combination on the proliferation of CRC cells were analyzed by MTT assay and colony formation assay. The effects of RES,IRI and their combination on the migration of CRC cells were assessed by Wound-healing assay. On this basis,the role of RES in regulating IRI chemoresistance of CRC cells and the underlying molecular mechanisms were further explored. Results The proliferation and migration ability of CRC cells in the RES and IRI combined treatment group were significantly lower than those in the IRI treated group, which showed that RES could enhance the inhibiting effect of IRI on the proliferation and migration of CRC cells, indicating that RES was able to a-meliorate the chemoresistance of CRC cells to IRI. And remarkably lower marker proteins expression levels of EGFR/AKT/mTOR signaling pathway in the RES and IRI combined treatment group was observed. Moreover, both EGFR activator (NSC 228155) and AKT activator (SC79) could reverse the ameliorating effect of RES on IRI chemoresistance of CRC cells, whereas AKT inhibitor (MK2206 ) could partially reverse the effect of NSC 228155. Conclusions RES can inhibit the proliferation and migration of CRC cells by down-regulating EGFR/AKT/mTOR signaling pathway, so as to ameliorate the chemoresistance of CRC cells to IRI, suggesting that RES combined with IRI can be a promising novel treatment for CRC.